NCT05102071

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Clinical and Economic Impact of 2nd Line Initiation of Empagliflozin After Metformin, as Compared to 2nd Line Initiation of Sulfonylurea After Metformin in Patients With Type 2 Diabetes and Cardiovascular Disease

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of clinical outcomes (specifically cardiovascular outcomes like hospitalization for heart failure), and healthcare cost, and resource utilization, among patients on empagliflozin as an add-on therapy to metformin versus patients on sulfonylureas as an add-on therapy to metformin in patients with Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD).

Conditions

• Diabetes Mellitus, Type 2
• Cardiovascular Diseases

Interventions

Type	Name	Description
DRUG	empagliflozin	empagliflozin
DRUG	metformin	metformin
DRUG	sulfonylurea	sulfonylurea

Timeline

• Start date: 2021-11-01
• Primary completion: 2022-06-15
• Completion: 2022-06-15
• First posted: 2021-11-01
• Last updated: 2022-06-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study